Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | TXNRD1 | Q16881 | 16/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | GSR | P00390 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31489882 | 0.79 | TXNRD1 (0.45) | HTTTXNRD1S1PR4MAPTS1PR1 | |
| SCHEMBL6027123 | 0.77 | TXNRD1 (0.51) | HTTTXNRD1S1PR4MAPTS1PR1 | |
| SCHEMBL1922830 | 0.76 | TDP1 (0.41) | HTTTDP1MAPT | |
| SCHEMBL336303 | 0.75 | TXNRD1 (0.56) | HTTTXNRD1S1PR4MAPTS1PR1 | |
| SCHEMBL31056308 | 0.75 | TXNRD1 (0.56) | HTTTXNRD1S1PR4MAPTS1PR1 | |
| SCHEMBL109187 | 0.75 | ALDH1A1 (0.41) | HTTTDP1MAPT | |
| SCHEMBL30078658 | 0.75 | ALDH1A1 (0.41) | HTTTDP1MAPT | |
| SCHEMBL27723339 | 0.73 | ALDH1A1 (0.46) | TDP1MAPT | |
| SCHEMBL17513283 | 0.72 | ALDH1A1 (0.39) | HTTTDP1MAPT | |
| SCHEMBL31288050 | 0.72 | S1PR4 (0.44) | TXNRD1TDP1S1PR4MAPTGSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250041319-A1 | BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | RIBOSCIENCE LLC | 2025-02-06 | — | — | US | disclosed |
| US-12029744-B2 | Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors | RIBOSCIENCE LLC (US) | 2024-07-09 | — | — | US | disclosed |
| EP-4249070-A2 | BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | Riboscience LLC (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20220362266-A1 | BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | RIBOSCIENCE LLC | 2022-11-17 | — | — | US | disclosed |
| EP-3952995-A1 | BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | Riboscience LLC (US) | 2022-02-16 | — | — | EP | disclosed |
| CN-114040915-A | Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors | 里伯赛恩斯有限责任公司 | 2022-02-11 | — | — | CN | disclosed |
| WO-2020210649-A1 | BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | RIBOSCIENCE LLC (US) | 2020-10-15 | — | — | WO | disclosed |
| US-20100317689-A1 | Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety | ALEVIUM PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
| WO-2008036201-A1 | PRODRUGS OF PROTON PUMP INHIBITORS INCLUDING THE 1H-IMIDAZO[4,5-B] PYRIDINE MOIETY | ALEVIUM PHARMACEUTICALS, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317689-A1 | Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety | ABCB11, ATP6AP1, CYP4B1 | HTT 2271/4885TXNRD1 3659/4885TDP1 3010/4885 |
| US-20250041319-A1 | BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | ENPP1, ENPP3, SMPD1 | HTT 3298/4885TXNRD1 1552/4885TDP1 153/4885 |
| US-12029744-B2 | Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors | ENPP1, ENPP3, SMPD1 | HTT 3278/4885TXNRD1 1600/4885TDP1 139/4885 |
| US-20220362266-A1 | BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | ENPP1, ENPP3, SMPD1 | HTT 3278/4885TXNRD1 1600/4885TDP1 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.